{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:06:48Z","timestamp":1793444808429,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The \u201cDengfeng\u201d Talent Training Program of Beijing Hospitals Authority","award":["Hong-Hu Zhu"],"award-info":[{"award-number":["Hong-Hu Zhu"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for lymphoid malignancies, its greatest challenge remains in the treatment of acute myeloid leukemia (AML). Its success in AML has been limited by the ideal target antigen, myelosuppression, and immunosuppressive leukemia microenvironment. The 2024 ASH Meeting highlighted several cutting-edge advancements in AML-directed CAR T therapies, including clinical trials targeting CD33, CD123, CLL1, CD19, and IL1RAP, as well as novel engineering strategies such as dual-targeting CARs, inhibitory CAR designs, and genome-editing approaches to enhance safety and efficacy. Here, we summarize key findings from both clinical and preclinical studies, offering insights into the evolving landscape of CAR T-cell therapy for AML.<\/jats:p>","DOI":"10.1186\/s40164-025-00651-6","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:07:59Z","timestamp":1744358879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024"],"prefix":"10.1186","volume":"14","author":[{"given":"Haixiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"Supplement 1","key":"651_CR1","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/blood-2024-207659","volume":"144","author":"Y Lin","year":"2024","unstructured":"Lin Y, Zhao D, Deng B, Liu D, Yan H, Li B, et al. The safety and efficacy of CD33 CAR-T therapy for RR AML after HSCT. Blood. 2024;144(Supplement 1):3467.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR2","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1182\/blood-2024-208795","volume":"144","author":"S Naik","year":"2024","unstructured":"Naik S, Renee M, Talleur AC, Epperly R, Lockey T, Bran J, et al. CD123-CAR T cells manufactured in the presence of dasatinib induce high grade CRS and\/or IEC-HS without improving efficacy in pediatric patients with recurrent\/refractory leukemia. Blood. 2024;144(Supplement 1):2076.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR3","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1182\/blood-2024-205229","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Bai X, Guo S, Zhang X, Zhao M. Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia. Blood. 2024;144(Supplement 1):2082.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR4","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.1182\/blood-2024-204381","volume":"144","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xiao X, Lv H, Bai X, Liu P, Pu Y, et al. Development of ThisCART371 targeting CLL1 for the treatment of relapsed\/refractory acute myeloid leukemia. Blood. 2024;144(Supplement 1):7210.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR5","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1182\/blood-2024-202265","volume":"144","author":"J Xu","year":"2024","unstructured":"Xu J, Zhang H, Zhao Y, Zhang X, Guo S, Lv H, et al. Distribution of infectious complications following CLL1 CAR-T cell therapy for R\/R AML: A Single-Center experience. Blood. 2024;144(Supplement 1):6018.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR6","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2024-194162","volume":"144","author":"MB Geyer","year":"2024","unstructured":"Geyer MB, DeWolf S, Mi X, Shaffer BC, Cadzin B, McAvoy D, et al. CD371-Targeted CAR T-Cells secreting Interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia. Blood. 2024;144(Supplement 1):2070.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR7","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1182\/blood-2024-207197","volume":"144","author":"J Yin","year":"2024","unstructured":"Yin J, Cui Q, Dai H, Li Z, Kang L, Cui W, et al. Unleashing the power of CD19 CAR-T in relapsed AML: findings from a prospective Single-Center clinical trial. Blood. 2024;144(Supplement 1):4836.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR8","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/blood-2024-205683","volume":"144","author":"HM Simpson","year":"2024","unstructured":"Simpson HM, Novak A, Danis C, Yarnell M, Duong P, Stevens BM, et al. CD64 CAR-T therapy targets Venetoclax-Resistant monocytic acute myeloid leukemia. Blood. 2024;144(Supplement 1):3416.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood-2024-205192","volume":"144","author":"R Zhang","year":"2024","unstructured":"Zhang R, Zhao Y, Zhao M. Modified dual CLL1-CD15 and CLL1-CD16 Icar-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia. Blood. 2024;144(Supplement 1):372.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2024-204895","volume":"144","author":"T Que","year":"2024","unstructured":"Que T, Rudden LS, Sobczyk A, Barth P, Arber C. Novel natural ligand chimeric antigen receptors (CARs) targeting CD70 with a redesigned CD27 binding interface provide enhanced potency against acute myeloid leukemia. Blood. 2024;144(Supplement 1):2032.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR11","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2024-201457","volume":"144","author":"JA Bejarano Garcia","year":"2024","unstructured":"Bejarano Garcia JA, Primo D, Palacios Barea MJ, Sierro B, Guijarro-Albaladejo B, Weng X, et al. Innovative bone marrow CAR-T cell manufacturing for AML: enhancing viability and tumor migration. Blood. 2024;144(Supplement 1):3478.","journal-title":"Blood"},{"issue":"Supplement 1","key":"651_CR12","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1182\/blood-2024-201322","volume":"144","author":"H Wang","year":"2024","unstructured":"Wang H, Liu L, Zhang C, Gao J, Lv L, Zhou L. Development of a novel allogeneic Super-\u0393\u03b4 T cell therapy for acute myeloid leukemia and multiple tumors. Blood. 2024;144(Supplement 1):2058.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00651-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:08:00Z","timestamp":1744358880000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00651-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00651-6","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}